Kruse CA - Search Results

1

Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2.

Kruse CA, Cepeda L, Owens B, Johnson SD, Stears J, Lillehei KO. Kruse CA, et al. Cancer Immunol Immunother. 1997 Oct;45(2):77-87. doi: 10.1007/s002620050405. Cancer Immunol Immunother. 1997. PMID: 9390198 Free PMC article.

2

Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy.

Lillehei KO, Mitchell DH, Johnson SD, McCleary EL, Kruse CA. Lillehei KO, et al. Among authors: kruse ca. Neurosurgery. 1991 Jan;28(1):16-23. doi: 10.1097/00006123-199101000-00003. Neurosurgery. 1991. PMID: 1994273 Clinical Trial.

3

Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take.

Kruse CA, Lillehei KO, Mitchell DH, Kleinschmidt-DeMasters B, Bellgrau D. Kruse CA, et al. Proc Natl Acad Sci U S A. 1990 Dec;87(24):9577-81. doi: 10.1073/pnas.87.24.9577. Proc Natl Acad Sci U S A. 1990. PMID: 2263613 Free PMC article.

4

Interleukin-2-activated lymphocytes from brain tumor patients. A comparison of two preparations generated in vitro.

Kruse CA, Mitchell DH, Lillehei KO, Johnson SD, McCleary EL, Moore GE, Waldrop S, Mierau GW. Kruse CA, et al. Cancer. 1989 Oct 15;64(8):1629-37. doi: 10.1002/1097-0142(19891015)64:8<1629::aid-cncr2820640813>3.0.co;2-d. Cancer. 1989. PMID: 2790675

5

Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma.

Kruse CA, Mitchell DH, Kleinschmidt-DeMasters BK, Bellgrau D, Eule JM, Parra JR, Kong Q, Lillehei KO. Kruse CA, et al. J Neurooncol. 1993 Feb;15(2):97-112. doi: 10.1007/BF01053931. J Neurooncol. 1993. PMID: 8509824

6

Characterization of a continuous human glioma cell line DBTRG-05MG: growth kinetics, karyotype, receptor expression, and tumor suppressor gene analyses.

Kruse CA, Mitchell DH, Kleinschmidt-DeMasters BK, Franklin WA, Morse HG, Spector EB, Lillehei KO. Kruse CA, et al. In Vitro Cell Dev Biol. 1992 Sep-Oct;28A(9-10):609-14. doi: 10.1007/BF02631035. In Vitro Cell Dev Biol. 1992. PMID: 1331021

7

Alveolar soft part sarcoma: an unusually long interval between presentation and brain metastasis.

Lillehei KO, Kleinschmidt-DeMasters B, Mitchell DH, Spector E, Kruse CA. Lillehei KO, et al. Among authors: kruse ca. Hum Pathol. 1993 Sep;24(9):1030-4. doi: 10.1016/0046-8177(93)90121-v. Hum Pathol. 1993. PMID: 8253458

8

Adjuvant adoptive immunotherapy for pediatric recurrent brain tumors.

Lillehei KO, Johnson SD, McCleary EL, Mitchell DH, Schiltz PM, Kruse CA. Lillehei KO, et al. Among authors: kruse ca. Online J Curr Clin Trials. 1993 Dec 29;Doc No 111:[806 words; 5 paragraphs]. Online J Curr Clin Trials. 1993. PMID: 8305997 Clinical Trial. No abstract available.

9

Neural cell adhesion molecule expression in human pituitary adenomas.

Kleinschmidt-DeMasters BK, Conway DR, Franklin WA, Lillehei KO, Kruse CA. Kleinschmidt-DeMasters BK, et al. Among authors: kruse ca. J Neurooncol. 1995;25(3):205-13. doi: 10.1007/BF01053153. J Neurooncol. 1995. PMID: 8592170

10

Allogeneic tumor-specific cytotoxic T lymphocytes.

Redd JM, Lagarde AC, Kruse CA, Bellgrau D. Redd JM, et al. Among authors: kruse ca. Cancer Immunol Immunother. 1992;34(5):349-54. doi: 10.1007/BF01741557. Cancer Immunol Immunother. 1992. PMID: 1371720 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

104 results

Search Page

Filters